[Distribution of phospholipids in platelet membranes and platelet factor 3 availability in patients with chronic kidney failure].
Patients with end-stage renal failure (ESRF) have a defect of haemostasis mainly caused by disturbances of platelet vessel wall interactions. An essential part in platelet function is played by the membrane phospholipids. The aim of this study was to estimate phospholipid distribution in platelet membrane and to evaluate the correlation between this distribution and PF3 availability. 18 non-dialysed (group I) and 21 chronically haemodialysed patients (group II) were studied. Phospholipid distribution was determined using TNBS tracer by the Vale method, and by phospholipase hydrolysis according to the modified Chap method. PF3 availability was estimated by the Saleem method. In group I membrane phospholipid distribution was unchanged as compared with control group, in this group decreased PF3 availability was also shown. In group II higher content of phosphatidylserine (PS) and phosphatidylethanolamine (PE) at the outer surface of platelet membrane was observed as compared with the healthy persons. In this group increased PF3 availability correlated with PS and PE exposition was also noted. It may reflects platelet activation in these patients. The different PF3 availability in non-dialysed and chronically haemodialysed patients suggests various pathogenesis of haemostasis disturbances in their patients.
Krawczyk
W
W
Oddziału Chorób Wewnetrznych Szpitala Wojewódzkiego w Chełmie.
Dmoszyńska
A
A
Ledwozyw
A
A
D000328:Adult; D000368:Aged; D001682:Biological Availability; D001792:Blood Platelets / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000378:metabolism*; D010977:Platelet Factor 3 / Q000378:metabolism*; D006435:Renal Dialysis
D010743:Phospholipids; D010977:Platelet Factor 3
Rozmieszczenie fosfolipidów błonowych krwinek płytkowych a dostepność 3 czynnika płytkowego u chorych z przewlekła niewydolnościa nerek.